• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colon Cancer

byDaniel GoldshteinandSze Wah Samuel Chan
June 17, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. No disease recurrences were observed during the median follow-up time of 26.2 months.

2. Immune-related adverse events grade 3-4 occurred in 4% of patients.

Evidence Rating Level: 2 (Good)

Study Rundown: While adjuvant chemotherapy is standard for locally advanced DNA mismatch repair deficiency (dMMR) colon cancer, recent studies advocate for neoadjuvant immunotherapy. This study (NICHE-2) evaluated neoadjuvant nivolumab plus ipilimumab’s efficacy in this setting. The primary endpoints included 3-year disease-free survival and timely surgery (no more than 2 weeks beyond the prespecified 6 weeks after study enrollment) and secondary endpoints included pathological response and safety. No disease recurrences were observed during the median follow-up time of 26.2 months. Pathological response rates were seen in 98% of patients, including 95% with a major pathological response and 68% with a pathological complete response. Pathological complete response was seen in a higher percentage of patients with Lynch syndrome than in those without (79% vs. 61%). Whole-exome sequencing data were done in most patients and found a median tumor mutational burden of 42.5 mutations per megabase (ranging from 3.46 to 138.7). The tumor mutational burden was not associated with pathological complete response nor was it associated with Lynch vs non-Lynch syndrome–associated tumors. BRAF V600E mutation was found in 57% of non–Lynch syndrome–associated tumors, and in those tumors, the pathological complete response was higher compared with BRAF V600 wild-type tumors (75% vs 57%). With regard to safety, timely surgery was performed in 98% of patients. 2% of patients had treatment-related adverse events (myositis) that led to delay of surgery. Immune-related adverse events grade 3-4 occurred in 4% of patients and included rash, asymptomatic increase in amylase and lipase levels, myositis, hepatitis, and hyponatremia. The strengths of this study included its follow-up time, and the limitations included its single-cohort design as well as the number of participants. Overall, this study found some efficacy and safety in patients with resectable stage II-III dMMR colon adenocarcinoma who were treated with neoadjuvant immunotherapy.

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

RELATED REPORTS

Atezolizumab may improve disease-free survival in mismatch repair deficiency locally advanced colon cancer

Neoadjuvant chemotherapy does not improve disease-free survival in patients with locally advanced colon cancer

In-Depth [prospective cohort]: This multicenter, single-arm, phase II trial enrolled adults (n=111) with resectable stage II or III dMMR colon adenocarcinoma and administered 2 doses of nivolumab and 1 dose of ipilimumab followed by surgery within 6 weeks of study enrollment. 33% of patients had Lynch syndrome, and 67% had stage III disease. Median follow-up time was 26.2 months (9.1 to 65.3), and no disease recurrences were observed. Pathological response rates were seen in 98% (95%CI, 94-100) of patients, including 95% (95%CI, 89 to 98) with a major pathological response and 68% (95%CI, 58-76) with a pathological complete response. Pathological complete response was seen in a higher percentage of patients with Lynch syndrome than of those without (79% vs. 61%). Whole-exome sequencing data were done in most patients and found a median tumor mutational burden of 42.5 mutations per megabase (ranging from 3.46 to 138.7). The tumor mutational burden was not associated with pathological complete response nor was it associated with Lynch vs non-Lynch syndrome–associated tumors. BRAF V600E mutation was found in 57% of non–Lynch syndrome–associated tumors, and in those tumors, the pathological complete response was higher compared with BRAF V600 wild-type tumors (75% vs 57%). With regards to safety, timely surgery was performed in 98% (97.5%CI, 93-100) of patients. 2% of patients had treatment-related adverse events (myositis) that led to delay of surgery. Immune-related adverse events grade 3-4 occurred in 4% of patients and included rash, asymptomatic increase in amylase and lipase levels, myositis, hepatitis, and hyponatremia. Overall, this study found some efficacy and safety in patients with resectable stage II-III dMMR colon adenocarcinoma who were treated with neoadjuvant immunotherapy.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: immunotherapyMMRMSI high
Previous Post

Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer

Next Post

#VisualAbstract: Patient Education Program May Reduce Disability and Symptoms of Chronic Pain

RelatedReports

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Oncology

Atezolizumab may improve disease-free survival in mismatch repair deficiency locally advanced colon cancer

April 8, 2026
Colorectal cancer collage: an engraved large intestine beside a blue awareness ribbon, a water bottle and a folded towel
Chronic Disease

Neoadjuvant chemotherapy does not improve disease-free survival in patients with locally advanced colon cancer

March 25, 2026
Biologic medicine supply collage: a steel bioreactor with Y-shaped antibodies rising from it, linked to a shipping container
All Specialties

Samsung BioLogics lands $1.3 billion U.S. contract amid tariff uncertainty

September 23, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
Next Post
#VisualAbstract: Patient Education Program May Reduce Disability and Symptoms of Chronic Pain

#VisualAbstract: Patient Education Program May Reduce Disability and Symptoms of Chronic Pain

#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma

#VisualAbstract: Neoadjuvant Nivolumab and Ipilimumab Improve Outcomes in Resectable Stage III Melanoma

#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH

#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
  • Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.